CLR 131 Shows Anti-tumor Activity, Safety in Difficult-to-treat B-cell Lymphoma Trial
News
Cellectar Biosciences has announced positive trial results demonstrating that its investigational therapy CLR 131 significantly reduced tumor activity, with tolerable safety, ... Read more